Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Basic) (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EPS (Basic) for 11 consecutive years, with -$3.57 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 2846.15% to -$3.57 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.02, a 54.03% increase, with the full-year FY2025 number at -$5.02, down 12.05% from a year prior.
  • EPS (Basic) was -$3.57 for Q4 2025 at Cartesian Therapeutics, down from -$1.38 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.61 in Q2 2025 to a low of -$43.71 in Q4 2023.
  • A 5-year average of -$3.28 and a median of -$0.12 in 2021 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 145800.0% in 2023, then surged 928.57% in 2024.
  • Cartesian Therapeutics' EPS (Basic) stood at $0.12 in 2021, then plummeted by 75.0% to $0.03 in 2022, then tumbled by 145800.0% to -$43.71 in 2023, then skyrocketed by 100.3% to $0.13 in 2024, then plummeted by 2846.15% to -$3.57 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EPS (Basic) are -$3.57 (Q4 2025), -$1.38 (Q3 2025), and $0.61 (Q2 2025).